about
Thrombotic stroke in a child with diarrhea-associated hemolytic-uremic syndrome with a good recovery.Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.IFN-γ and TNF-α synergistically induce microRNA-155 which regulates TAB2/IP-10 expression in human mesangial cells.Tacrolimus monotherapy in a patient with lupus flare using once-daily administration protocolInflammatory chemokine expression via Toll-like receptor 3 signaling in normal human mesangial cells.Autoantibodies to villin occur frequently in IPEX, a severe immune dysregulation, syndrome caused by mutation of FOXP3.Mizoribine in the treatment of pediatric-onset glomerular disease.Interferon (IFN)-induced protein 35 (IFI35) negatively regulates IFN-β-phosphorylated STAT1-RIG-I-CXCL10/CCL5 axis in U373MG astrocytoma cells treated with polyinosinic-polycytidylic acid.Interferon-stimulated gene (ISG) 60, as well as ISG56 and ISG54, positively regulates TLR3/IFN-β/STAT1 axis in U373MG human astrocytoma cells.Desferrioxamine, an iron chelator, inhibits CXCL10 expression induced by polyinosinic-polycytidylic acid in U373MG human astrocytoma cells.Carnosic acid attenuates apoptosis induced by amyloid-β 1-42 or 1-43 in SH-SY5Y human neuroblastoma cells.ISG54 and ISG56 are induced by TLR3 signaling in U373MG human astrocytoma cells: possible involvement in CXCL10 expression.Carnosic acid suppresses the production of amyloid-β 1-42 and 1-43 by inducing an α-secretase TACE/ADAM17 in U373MG human astrocytoma cells.Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy.Successful multidrug treatment of a pediatric patient with severe Churg-Strauss syndrome refractory to prednisolone.Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis.Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy.Complete occulusion of left renal artery in pediatric-onset Takayasu's arteritis.Acute tubulointerstitial nephritis following intravenous immunoglobulin therapy in a male infant with minimal-change nephrotic syndrome.Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab.Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1 in human mesangial cells.Glomerular expression of myxovirus resistance protein 1 in human mesangial cells: possible activation of innate immunity in the pathogenesis of lupus nephritis.Tumor necrosis factor-α synergistically enhances polyinosinic-polycytidylic acid-induced toll-like receptor 3 signaling in cultured normal human mesangial cells: possible involvement in the pathogenesis of lupus nephritis.Mizoribine selectively attenuates monocyte chemoattractant protein-1 production in cultured human glomerular mesangial cell: a possible benefit of its use in the treatment of lupus nephritis.Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis.Benefits of once-daily administration of cyclosporine a for children with steroid-dependent, relapsing nephrotic syndrome.Repeat renal biopsy in a girl with tubulointerstitial nephritis and uveitis syndrome.TLR4 signaling induces retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5 in mesangial cells.Successful treatment with leukocytapheresis in refractory Henoch-Schönlein purpura: case report.End-stage kidney at the onset of nephrotic syndrome in a 4-year-old girl.Effective therapy of a child case of refractory nephrotic syndrome with tacrolimus.Interaction between interferon-stimulated gene 56 and melanoma differentiation-associated gene 5 in Toll-like receptor 3 signaling in normal human mesangial cells.Use of recombinant human serum albumin in pediatric patients with nephrotic syndrome.A novel multidrug therapy for difficult cyclosporine-resistant focal segmental glomerulosclerosis.Single-dose daily administration of cyclosporin A for refractory nephrotic syndrome.Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis.Cylindromatosis (CYLD), a Deubiquitinase, Attenuates Inflammatory Signaling Pathways by Activating Toll-Like Receptor 3 in Human Mesangial Cells.DEC1 negatively regulates the expression of CXCL10 and CCL5 induced by poly IC in normal human mesangial cells.Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells.Acute renal failure with encephalopathy following Salmonella enteritidis infection.
P50
Q33337025-BD3E0393-3F4A-4915-BC3B-90610ED42B68Q33371558-B04F9D4B-4146-4B77-B2C5-EBC6C0CD01BAQ34143758-BB7C31BE-C2AA-4079-8872-2E3AFC81E0ACQ35574588-1D5367FE-0C0E-4006-9FB6-A5B5AF6A75D2Q38128300-E81A7DC1-01DE-47F7-A7AF-BE755F68846CQ38333583-E0DC656D-EE74-46B3-89AA-CE63BF962EF3Q38371253-D17A970B-4BEA-4740-A3E6-1C07A62A7E9EQ38720145-2AB1E783-962F-4232-9F77-D9F7945C48FAQ38831250-AD895277-4609-4F3E-82D5-2DF6C6042574Q38919645-EC56936A-0050-4002-A394-71644498C9D5Q38928446-3478FF3E-212B-456A-AFD4-499BD9480ECAQ39015493-820A053F-AF97-4E79-A92D-AF91857B788BQ39051200-9F80E4C4-C309-483C-9002-680FBBA25CE2Q39160729-739FEB18-2669-49C5-A3DC-075AC0341E58Q40312192-791F5810-EEDB-4BCE-959E-1C2659C48384Q40354638-7B6F295D-82FB-42A9-BB7C-8E2CAB7D72A1Q40363551-800BCC1D-014A-4254-98C1-4FAA987F9C5EQ40619173-F0B9D68A-0FC6-4827-8918-441A19E20C96Q40622835-F71045C0-36D9-487A-80C8-AA5E12A7D4A3Q40760159-C13044F4-1FBA-4526-90D6-B1384AD4F239Q42177722-63A092F3-3AC3-468C-8672-A4F102AAEC6EQ42228695-25659EDC-C0F7-4A5C-A6AA-2F87107C6362Q42231646-F6512BC2-E730-4B6C-B6D1-545F41AFA79BQ42261783-6CF0FDB4-3C45-412C-AB20-360EBEA35031Q43057636-0617A301-D8A9-4F5D-8075-036107866C55Q43140336-D840A8EF-65F5-41B4-BA70-B9FBDAACC1EAQ43784006-173EC79F-D94A-469F-A85D-38A2863416EAQ43887392-F84BF721-D7BF-405C-A635-3EDE3A3B69B7Q44593373-D52B40AE-4259-4410-ACEF-4B4F08A6057AQ44604046-4F272595-FEC2-4B65-8ABD-CB4FEACE7DB1Q45122447-FAC4B95F-3454-477A-A84D-6590EE181C7CQ45835026-84BB3051-9EBD-4CF8-9539-F8C37935DD79Q45993284-D9D182A2-24ED-4B8B-AB46-A002A8D0FAC3Q46299037-3DDC7281-631B-4B02-AEF0-BCA10FC281D2Q46473241-2DCF4888-6E09-4BDD-9465-B282D3088782Q46549975-61B18012-081F-4A7E-BBC8-5942CE3883F8Q47373299-EACB44A7-D73F-4ACE-8375-819927ED816DQ47971064-CB80E967-3E3E-445C-8506-73E7711ED335Q48361268-9E905570-8D6A-4851-B4EF-A7763403DFCDQ48524616-633E67B5-47FC-4941-BC6B-FDA92881B31F
P50
description
researcher ORCID ID=0000-0001-7057-813X
@en
name
H Tanaka
@en
H Tanaka
@nl
type
label
H Tanaka
@en
H Tanaka
@nl
prefLabel
H Tanaka
@en
H Tanaka
@nl
P106
P31
P496
0000-0001-7057-813X